1832 Asset Management
LKFT

1832 Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

1832 Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-65,000
Closed -$13.6M – 707
2019
Q4 		$13.6M Buy
+65,000
New +$12M 0.04% 214

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

1832 Asset Management's LKFT Position: Q1 2020 in Review

1832 Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2020, closing a stake of 65,000 shares — an estimated $13.6M sold.

1832 Asset Management first reported a position in LKFT in Q4 2019 and held it in 1 quarter. The position peaked at $13.6M in Q4 2019. 141 funds tracked by Wall St. Rank hold LKFT as of Q1 2020.

  • 1832 Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2020 after selling out during the quarter.
  • 1832 Asset Management sold 65,000 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2020, an estimated $13.6M.
  • 1832 Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and held it in 1 quarter.
  • 1832 Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $13.6M in Q4 2019.
  • 141 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2020.

Based on 1832 Asset Management's 13F filing for Q1 2020, filed 14 May 2020.